Pozen, Teva Bury Hatchet Over Treximet

Law360, New York (April 14, 2010, 3:21 PM EDT) -- Pozen Inc. has reached a settlement with Teva Pharmaceuticals USA Inc. in a patent suit over Teva's plans for a generic version of the migraine treatment Treximet, marketed in the U.S. by GlaxoSmithKline PLC.

Pozen and Teva filed a joint stipulation dismissing Teva from the case and discussing the settlement on Wednesday in the U.S. District Court for the Eastern District of Texas. The settlement is the first in the case, in which Pozen has accused three other generics makers of infringement.

The case remains pending...
To view the full article, register now.